克利夫兰临床研究发现血压药会减慢冠心病的进展 与（文档。文档元素]）{ 名=类名。取代（\/ \ BNO JS \ \/，“JS”）； } 如果（文件的URL。substring（7，9）= =“我”

堵塞和动脉硬化的人有他们的血压控制的患者可能会从一个额外的降血压药物的好处，据克利夫兰临床临床研究中心协作研究（c5research）。

研究人员发现，肾素抑制剂阿利吉仑趋于减缓冠状动脉疾病的进展和减少死亡的风险，约百分之50患者的中风和心脏病发作，与安慰剂比较，提示高血压前期患者可以从降压药物效益。

水瓶座的结果（阿利吉仑定量动脉粥样硬化消退的血管内超声研究）试验了今天在欧洲心脏病学协会2013并同时发表在美国医学会杂志。

Aliskiren affects the body’s renin-angiotensin-aldosterone system (RAAS), a hormone system that regulates blood pressure and has been shown in prior studies to play an important role in the development of atherosclerosis, or the hardening or clogging of the arteries。 As a renin inhibitor, aliskiren partially blocks renin from triggering the RAAS process and is approved to treat hypertension to optimal guidelines of 140/90 mmHg, or the high end of the prehypertensive range。

AQUARIUS, a prospective, randomized, multicenter, double-blind clinical trial, was designed to test whether renin inhibition could slow or reverse the progression of coronary artery disease in patients who have their blood pressure under control in the prehypertensive range。 The study also looked at whether these patients would benefit from additional blood pressure-lowering medication, even though their blood pressure was considered to be under control。

A team of researchers led by Stephen J。 Nicholls, MD, Ph D, senior consultant to Cleveland Clinic’s C5Research and Professor of Cardiology and Deputy Director at the South Australian Health & Medical Research Institute (SAHMRI) in Adelaide, Australia, used intravascular ultrasonography (IVUS) to assess the degree of coronary disease progression in 458 patients at baseline and after 104 weeks of treatment with aliskiren or placebo。 IVUS is a medical imaging technology in which a small ultrasound probe is inserted via a catheter into an artery, allowing physicians to examine the inside of arteries via sonogram。

“We found that aliskiren had a moderate effect on reducing blood pressure, substantially reduced renin activity, and produced a compensatory increase in renin concentration in the blood plasma,” Dr。 Nicholls said。 “We also saw a bit of a trend toward regression in atherosclerosis。 But our primary endpoint – a decrease in the volume of disease in the artery – did not meet statistical significance。”

Although not a primary endpoint, the researchers did identify a decrease in major cardiovascular events including sudden death, stroke, and heart attack in patients on aliskiren。 The data indicate that patients with heart disease and blood pressure in the prehypertensive range may benefit from more aggressive treatment of their blood pressure to get it lower than current guidelines suggest。

“We have to be cautious interpreting our results on cardiovascular events because this trial was not formally designed to look at these outcomes,” said Steven Nissen, MD, Chairman of the AQUARIUS trial executive committee and Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic。 “However, the data indicate that renin inhibition is safe in patients who have coronary artery disease and have their blood pressure under control, and it may have some beneficial cardiovascular effects。”

AQUARIUS was an academically directed trial, funded by Novartis Pharmaceuticals and governed by an independent executive committee。

（注：转载时请注明复诊网）